Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seres Therapeutics Inc.

www.serestherapeutics.com

Latest From Seres Therapeutics Inc.

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Microbiome Drug Development: An Investigation Into Challenges And Innovative Pipeline Approaches

The discovery and deep investigation of the microbiome has been one of the most cutting-edge advances in biomedical research of recent times, but as the science moves forward new hurdles are emerging for microbiome therapies.

Innovation Gastrointestinal

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy.

South Korea Research & Development

MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too

Emerging Company Profile: Calling itself the most advanced microbiome company focused on skin diseases, MatriSys has advanced a proprietary microbe to Phase IIa for atopic dermatitis. The biotech also is eyeing UV-induced cancer, rosacea, acne, psoriasis and bacterial skin infections.

StartUps and SMEs Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Seres Health Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Seres Therapeutics Inc.
  • Senior Management
  • Eric Shaff, Pres. & CEO
    Matthew Henn, PhD, CSO
    Kevin Horgan, MD, EVP, CMO
  • Contact Info
  • Seres Therapeutics Inc.
    Phone: (617) 945-9626
    200 Sidney St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register